Abbott Laboratories Corporation

Richard L Elliott

Nan-Horng Lin

Yat Sun Or

Daniel T Chu

Yun He

Mark W Holladay

Daisy Pireh

David E Gunn, Jr

Jacob J Plattner

Ly Tam Phan

Michael J Dart

Jerome F Daanen

William H Bunnelle

Melwyn A Abreo

Michael D Tufano

Steven J Wittenberger

Keith Brian Ryther

Robert Hallas

George W Griesgraber

Hana A Kopecka

Yihong Li

James T Wasicak

Suzanne A Lebold

Pulla Reddy Singam

Kenneth P Spina

Bikshandar A Narayanan

Mukund S Chorghade

Dieter O Beer

Christian C Witzig

Thomas C Herzig

Thomas K Esch

Alla V Rama Rao

Compounds, or pharmaceutically acceptable salts and esters thereof, of the formula:

Tricyclic erythromycin derivatives

Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.

Furopyridine, thienopyridine pyrrolopyridine useful in controlling

Novel heterocyclic ether compounds of the formula: ##STR1## wherein *, A,B, n, R.sup.1, R.sup.2 and X are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are useful in selectively activating or inhibiting neurotransmitter release; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to activate or inhibit neurotransmitter release in mammals.

Heterocyclic ether compounds useful in controlling neurotransmitter

Novel 3-descladinose-2,3-anhydroerythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity.

3-descladinose-2,3-anhydroerythromycin derivatives

A compound selected from the group: ##STR1## wherein A, B, V, W, X and R.sup.8 are specifically defined; pharmaceutical compositions thereof; a method of treating or preventing bacterial infections by administering therapeutically effective pharmaceutical compositions thereof; and a process for the preparation thereof.

3-deoxy-3-descladinose derivatives of erythromycins A and B

Selective and potent cholinergic ligands selective for neuronal nicotinic cholinergic channel receptors, which ligands have the formula: ##STR1## as well as pharmaceutically-acceptable salts or prodrugs thereof, which are useful in the treatment of dementias, attentional hyperactivity disorder, or substance abuse withdrawal characterized by decreased cholinergic function, one of which is also an analgesic agent, and one of which is an agent useful for treating anxiety associated with cognitive impairment.

2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive

A novel process for preparing enantiomerically-pure 3-methyl-5-(1-(C.sub.1 -C.sub.3 -alkyl)-2-pyrrolidinyl)isoxazole in high yield, wherein a protected pyrrolidine or 2-oxo-pyrrolidine starting material is reacted with a suitable organic anion and a resulting beta-keto oxime intermediate is cyclized and dehydrated, as well as intermediates useful in the preparation thereof.

Method of preparing enantiomerically-pure

Growing community of inventors

Grayslake, IL, United States of America

Richard L Elliott